<DOC>
	<DOC>NCT02456103</DOC>
	<brief_summary>This is an open-label extension study for patients who complete a Phase 3, placebo-controlled study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.</brief_summary>
	<brief_title>Extension Study of Ataluren for Nonsense Mutation Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Completion of study treatment (placebo or active) in the previous Phase 3, doubleblind study protocol (Protocol PTC124GD021CF) Ongoing participation in any other therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>